Skip to main content
. 2020 Jul 16;11:1410. doi: 10.3389/fimmu.2020.01410

Figure 9.

Figure 9

BEN compared to CY treatment results in greater expression of Flt3 receptor and the inhibitory receptor PIR-B on cDCs. BALB/c mice received 40 mg/kg BEN or 200 mg/kg CY on day −2. (A) On day 0, blood plasma was collected and used in an ELISA to determine circulating levels of Flt3 Ligand. Naïve mice were used as a control. Mann-Whitney unpaired t-tests were used to determine significance with SEM shown. (B,C) On day 0, splenic DCs were isolated by MACS negative selection and analyzed by flow cytometry. Representative histograms, percent and MFI of Flt3 receptor on (B) CD11c+ DCs (C) cDCs (CD11c+B220-) and (D) CD8α+ cDC1s positively expressing Flt3 receptor are shown for BEN (blue) and CY (red) treated mice, with FMO control shown in gray. Data is pooled from 2 experiments, n = 6 mice per group. Mann-Whitney unpaired t-tests were used to determine significance with SEM shown. *P < 0.05, **P < 0.01. (E) BALB/c mice received 40 mg/kg BEN or 200 mg/kg CY on day −2 and 400 cGy TBI on day −1. On day 0, splenic DCs were isolated by MACS negative selection and analyzed by flow cytometry. Representative histograms, percent positive (P = 0.50) and MFI (P = 0.092) of PIR-B on cDCs (CD11c+B220-) are shown for BEN+TBI and CY+TBI conditioned mice. Data is pooled from 2 experiments, n = 5 mice per group. Mann-Whitney unpaired t-test was used to determine significance with SEM shown.